Long before medical devices became headline-worthy in India, Meril was quietly building world-class tech in Vapi, Gujarat. Now its parent company, Micro Life Sciences, has entered the global growth stage.
Sovereign Backing & IPO Readiness
In early 2025, global investors Temasek and the Abu Dhabi Investment Authority (ADIA) signaled big-ticket interest preparing to invest $250–300 million in Micro Life ahead of its anticipated IPO within 12–18 months. The deal values the company at an estimated ₹65,000 crore (~$7.8B) a steep leap from the $1.8B valuation at which Warburg Pincus invested in 2022.
Why This Round Matters
- It enables a mix of primary funding and secondary share sales, bringing fresh capital while also providing existing shareholders liquidity.
- Meril Life Sciences, Micro Life’s flagship, is known for pioneering Myval TAVR valves, MeRes100 bioresorbable scaffolds, surgical robots (MISSO), and now MyClip for mitral valve repair.
- Micro reported ₹3,495 Cr revenue in FY24, up from ₹2,359 Cr in FY23; EBITDA stands near ₹1,300 Cr, with improved margins (72.8%).
Building India’s MedTech Powerhouse
Founded in 2006 by the Bilakhia family, Meril now exports to 100+ countries, holds market leadership in knee implants, and has 8 manufacturing facilities across India with over 8,000 employees. This investment would fuel global expansion, accelerate R&D, and improve clinical trial outreach.
Sovereign wealth support from ADIA and Temasek not only validates “Made-in-India” medical innovation but also aligns with India’s PLI‑driven medtech push.
What Comes Next
Micro Life is positioned for an IPO estimated around ₹65,000 Cr within 2026–27. The funding will solidify its position as India’s largest medical devices exporter and support its deep tech products through regulatory approvals worldwide.
Follow StartupstoryIndia for more deep insights into India’s next wave of industrial scale up stories from medtech to mobility.
